All Stories

  1. CAM3.0: determining cell type composition and expression from bulk tissues with fully unsupervised deconvolution
  2. Beyond October, Beyond Pink: A Year-Round Revelation for Women's Breast Health
  3. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer
  4. Social Isolation Activates Dormant Mammary Tumors, and Modifies Inflammatory and Mitochondrial Metabolic Pathways in the Rat Mammary Gland
  5. The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness
  6. Introduction: Cancer Systems and Integrative Biology
  7. Mathematical Models of Death Signaling Networks
  8. Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux
  9. AMPK Signaling Regulates Mitophagy and Mitochondrial ATP Production in Human Trophoblast Cell Line BeWo
  10. Comparative assessment and novel strategy on methods for imputing proteomics data
  11. COT: an efficient and accurate method for detecting marker genes among many subtypes
  12. Cosbin: cosine score-based iterative normalization of biologically diverse samples
  13. swCAM: estimation of subtype-specific expressions in individual samples with unsupervised sample-wise deconvolution
  14. A Bayesian approach for accurate de novo transcriptome assembly
  15. ChIP-GSM: Inferring active transcription factor modules to predict functional regulatory elements
  16. Inhibition of Antiestrogen-Promoted Pro-Survival Autophagy and Tamoxifen Resistance in Breast Cancer through Vitamin D Receptor
  17. ChIP-BIT2: a software tool to detect weak binding events using a Bayesian integration approach
  18. Data-driven detection of subtype-specific differentially expressed genes
  19. Identifying intracellular signaling modules and exploring pathways associated with breast cancer recurrence
  20. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
  21. Experimental models of endocrine responsive breast cancer: strengths, limitations, and use
  22. Author Correction: BICORN: An R package for integrative inference of de novo cis-regulatory modules
  23. IntAPT: integrated assembly of phenotype-specific transcripts from multiple RNA-seq profiles
  24. IκB kinase-ε-mediated phosphorylation triggers IRF-1 degradation in breast cancer cells
  25. Radiogenomic signatures reveal multiscale intratumour heterogeneity associated with biological functions and survival in breast cancer
  26. Maternal obesity increases offspring’s mammary cancer recurrence and impairs tumor immune response
  27. Preface
  28. A systems biology approach to discovering pathway signaling dysregulation in metastasis
  29. BICORN: An R package for integrative inference of de novo cis-regulatory modules
  30. debCAM: a bioconductor R package for fully unsupervised deconvolution of complex tissues
  31. RNA interference screening methods to identify proliferation determinants and mechanisms of resistance to immune attack
  32. Biomedical image characterization and radiogenomics
  33. Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer
  34. Systems biology: perspectives on multiscale modeling in research on endocrine-related cancers
  35. Estrogen-Induced Apoptosis in Breast Cancers Is Phenocopied by Blocking Dephosphorylation of Eukaryotic Initiation Factor 2 Alpha (eIF2α) Protein
  36. Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model
  37. Microbiome signatures in prostate cancer
  38. SLCs contribute to endocrine resistance in breast cancer: role of SLC7A5 (LAT1)
  39. Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells
  40. Introduction: The Unfolded Protein Response
  41. Role of Protein Translation in Unfolded Protein Response
  42. Roles of Spliced and Unspliced XBP1 in Breast Cancer
  43. The Unfolded Protein Response as an Integrator of Response to Endocrine Therapy in Estrogen Receptor Positive Breast Cancer
  44. Dielectrophoretic properties distinguish responses to estrogen and fulvestrant in breast cancer cells
  45. Autophagy and unfolded protein response (UPR) regulate mammary gland involution by restraining apoptosis-driven irreversible changes
  46. CRNET: an efficient sampling approach to infer functional regulatory networks by integrating large-scale ChIP-seq and time-course RNA-seq data
  47. SparseIso: a novel Bayesian approach to identify alternatively spliced isoforms from RNA-seq data
  48. Breast cancer cell obatoclax response characterization using passivated-electrode insulator-based dielectrophoresis
  49. EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer
  50. Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats
  51. CyNetSVM: A Cytoscape App for Cancer Biomarker Identification Using Network Constrained Support Vector Machines
  52. Autophagy, Inflammation, and Breast Cancer Risk
  53. RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells
  54. Introduction: Cancer Gene Networks
  55. Endoplasmic Reticulum Stress Protein GRP78 Modulates Lipid Metabolism to Control Drug Sensitivity and Antitumor Immunity in Breast Cancer
  56. Biologically inspired survival analysis based on integrating gene expression as mediator with genomic variants
  57. PSSV: a novel pattern-based probabilistic approach for somatic structural variation identification
  58. DM-BLD: differential methylation detection using a hierarchical Bayesian model exploiting local dependency
  59. Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model
  60. Social isolation induces autophagy in the mouse mammary gland: link to increased mammary cancer risk
  61. G-DOC Plus – an integrative bioinformatics platform for precision medicine
  62. Erratum
  63. Mathematical modelling of transcriptional heterogeneity identifies novel markers and subpopulations in complex tissues
  64. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
  65. ChIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of ChIP-seq profiles
  66. Endocrine resistance in breast cancer – An overview and update
  67. A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance
  68. BACOM2.0 facilitates absolute normalization and quantification of somatic copy number alterations in heterogeneous tumor
  69. TMEM33: a new stress-inducible endoplasmic reticulum transmembrane protein and modulator of the unfolded protein response signaling
  70. Role of GRP78 in promoting therapeutic-resistant breast cancer
  71. Overcoming cancer resistance
  72. Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation
  73. Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers
  74. BMRF-MI: integrative identification of protein interaction network by modeling the gene dependency
  75. Linking autophagy with inflammation through IRF1 signaling in ER+ breast cancer
  76. Dynamic Modeling of the Interaction Between Autophagy and Apoptosis in Mammalian Cells
  77. Interferon Regulatory Factor-1 Signaling Regulates the Switch between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate
  78. BMRF-Net: a software tool for identification of protein interaction subnetworks by a bagging Markov random field-based method: Fig. 1.
  79. Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement
  80. Recommendations concerning the new U.S. National Institutes of Health initiative to balance the sex of cells and animals in preclinical research
  81. Application of Metabolomics in Drug Resistant Breast Cancer Research
  82. Molecular mechanisms of tamoxifen-associated endometrial cancer (Review)
  83. The Changing Spectrum of Biomedical and Clinical Research
  84. Blockage of Lysosomal Degradation Is Detrimental to Cancer Cell Survival
  85. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer
  86. Small-Molecule “BRCA1-Mimetics” Are Antagonists of Estrogen Receptor-α
  87. Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance
  88. When is a vesicle not just a vesicle: mitochondrial spheroids and mitochondrial autophagosomes
  89. Unsupervised Deconvolution of Dynamic Imaging Reveals Intratumor Vascular Heterogeneity and Repopulation Dynamics
  90. NF-κB Signaling Is Required for XBP1 (Unspliced and Spliced)-Mediated Effects on Antiestrogen Responsiveness and Cell Fate Decisions in Breast Cancer
  91. Integration of Network Biology and Imaging to Study Cancer Phenotypes and Responses
  92. ERβ decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway
  93. Estrogen receptor-α signaling and localization regulates autophagy and unfolded protein response activation in ER+ breast cancer
  94. Integrating Proteotoxic Stress Response Pathways for Induction of Cell Death in Cancer Cells: Molecular Mechanisms and Therapeutic Opportunities
  95. KDDN: an open-source Cytoscape app for constructing differential dependency networks with significant rewiring
  96. UNDO: a Bioconductor R package for unsupervised deconvolution of mixed gene expressions in tumor samples
  97. Correction: Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?
  98. BADGE: A novel Bayesian model for accurate abundance quantification and differential analysis of RNA-Seq data
  99. BSSV: Bayesian based somatic structural variation identification with whole genome DNA-seq data
  100. Knowledge-fused differential dependency network models for detecting significant rewiring in biological networks
  101. Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?
  102. Hydroxychloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer
  103. Knockdown of estrogen receptor‐α induces autophagy and inhibits antiestrogen‐mediated unfolded protein response activation, promoting ROS‐induced breast cancer cell death
  104. Autophagy inhibitor 3-methyladenine potentiates apoptosis induced by dietary tocotrienols in breast cancer cells
  105. Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer
  106. A Markov random field-based Bayesian model to identify genes with differential methylation
  107. Robust identification of transcriptional regulatory networks using a Gibbs sampler on outlier sum statistic
  108. Maternal exposure to diethylstilbestrol during pregnancy and increased breast cancer risk in daughters
  109. Mitochondria directly donate their membrane to form autophagosomes during a novel mechanism of parkin-associated mitophagy
  110. Blockage of Lysosomal Degradation is Detrimental to Cancer Cell Survival
  111. Glutamine metabolism and the unfolded protein response in MYC-driven breast cancer
  112. MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer
  113. Inhibiting glucose-regulated protein 78 modulates lipid metabolism through controlling stearoyl-CoA desaturase 1
  114. VAV3 mediates resistance to breast cancer endocrine therapy
  115. Integrative Analysis Workflow for Untargeted Metabolomics in Translational Research
  116. Statistical Identification of Co-regulatory Gene Modules using Multiple ChIP-Seq Experiments
  117. A novel statistical approach to identify co-regulatory gene modules
  118. mAPC-GibbsOS: an integrated approach for robust identification of gene regulatory networks
  119. AISAIC: a software suite for accurate identification of significant aberrations in cancers
  120. Reconstruction of Transcriptional Regulatory Networks by Stability-Based Network Component Analysis
  121. Reconstructing transcriptional regulatory networks by probabilistic network component analysis
  122. Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells
  123. Modelling the effect of GRP78 on anti-oestrogen sensitivity and resistance in breast cancer
  124. ANTIHORMONE DRUG RESISTANCE
  125. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers
  126. Monoclonal Antibody against the Ectodomain of E-Cadherin (DECMA-1) Suppresses Breast Carcinogenesis: Involvement of the HER/PI3K/Akt/mTOR and IAP Pathways
  127. Targeting GRP78 and antiestrogen resistance in breast cancer
  128. GX15-070 (Obatoclax) Induces Apoptosis and Inhibits Cathepsin D- and L–Mediated Autophagosomal Lysis in Antiestrogen-Resistant Breast Cancer Cells
  129. Advancing Translational Research through Facility Design in Non-AMC Hospitals
  130. Module-based breast cancer classification
  131. Genomic and network analysis to study the origin of ovarian cancer
  132. In Silico Discovery of Mitosis Regulation Networks Associated with Early Distant Metastases in Estrogen Receptor Positive Breast Cancers
  133. Identifying Early Events of Gene Expression in Breast Cancer with Systems Biology Phylogenetics
  134. Heat shock 70 kDa protein 5/glucose-regulated protein 78 “AMP”ing up autophagy
  135. Accurate identification of significant aberrations in contaminated cancer genome
  136. Sampling-Based Subnetwork Identification from Microarray Data and Protein-Protein Interaction Network
  137. Identifying protein interaction subnetworks by a bagging Markov random field-based method
  138. Regulatory component analysis: A semi-blind extraction approach to infer gene regulatory networks with imperfect biological knowledge
  139. Genome-wide identification of significant aberrations in cancer genome
  140. Glucose-Regulated Protein 78 Controls Cross-talk between Apoptosis and Autophagy to Determine Antiestrogen Responsiveness
  141. Antiestrogen resistance and the application of systems biology
  142. Robust identification of transcriptional regulatory networks using a Gibbs sampler on outlier sum statistic
  143. Tyrosine-phosphorylated Caveolin-1 (Tyr-14) Increases Sensitivity to Paclitaxel by Inhibiting BCL2 and BCLxL Proteins via c-Jun N-terminal Kinase (JNK)
  144. Interaction of dietary polyphenols with molecular signaling pathways of antiestrogen resistance: possible role in breast cancer recurrence
  145. Guidelines for the use and interpretation of assays for monitoring autophagy
  146. Endoplasmic Reticulum Stress, the Unfolded Protein Response, Autophagy, and the Integrated Regulation of Breast Cancer Cell Fate
  147. Influence of Berry Polyphenols on Receptor Signaling and Cell-Death Pathways: Implications for Breast Cancer Prevention
  148. Effect of Berry Extracts and Bioactive Compounds on Fulvestrant (ICI 182,780) Sensitive and Resistant Cell Lines
  149. Gamma-tocotrienol induced apoptosis is associated with unfolded protein response in human breast cancer cells
  150. Pregnancy hormonal environment and mother’s breast cancer risk
  151. Reconstruction of Transcription Regulatory Networks by Stability-Based Network Component Analysis
  152. Identifying cancer biomarkers by network-constrained support vector machines
  153. NTP-CERHR expert panel report on the developmental toxicity of soy infant formula
  154. G-DOC: A Systems Medicine Platform for Personalized Oncology
  155. Vitamin E succinate inhibits survivin and induces apoptosis in pancreatic cancer cells
  156. Cannibalism, cell survival, and endocrine resistance in breast cancer
  157. Autophagy and endocrine resistance in breast cancer
  158. GIST: A Gibbs sampler to identify intracellular signal transduction pathways
  159. Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells
  160. Overexpression of the Dominant-Negative Form of Interferon Regulatory Factor 1 in Oligodendrocytes Protects against Experimental Autoimmune Encephalomyelitis
  161. Profile of Robert Clarke
  162. Abstract 2070: XBP-1 promotes cell survival by activating the unfolded protein response (UPR) in antiestrogen resistance in breast cancer
  163. Abstract LB-148: XBP1 regulates NFkappaB signaling in antiestrogen resistant breast cancer cells
  164. Motif-guided sparse decomposition of gene expression data for regulatory module identification
  165. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
  166. Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer
  167. DDN: a caBIG® analytical tool for differential network analysis
  168. The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer
  169. G-CODE: enabling systems medicine through innovative informatics
  170. PUGSVM: a caBIGTM analytical tool for multiclass gene selection and predictive classification
  171. Module-based biomarker discovery in breast cancer
  172. Identification of Transcriptional Regulatory Networks by Learning the Marginal Function of Outlier Sum Statistic
  173. Differential Dependency Network Analysis to Identify Topological Changes in Biological Networks
  174. Changes in mammary caveolin-1 signaling pathways are associated with breast cancer risk in rats exposed to estradiol in utero or during prepuberty
  175. Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response
  176. The Proapoptotic Molecule BLID Interacts with Bcl-XL and Its Downregulation in Breast Cancer Correlates with Poor Disease-Free and Overall Survival
  177. IFNγ Restores Breast Cancer Sensitivity to Fulvestrant by Regulating STAT1, IFN Regulatory Factor 1, NF-κB, BCL2 Family Members, and Signaling to Caspase-Dependent Apoptosis
  178. Reconstruction of Gene Regulatory Modules in Cancer Cell Cycle by Multi-Source Data Integration
  179. Multilevel support vector regression analysis to identify condition-specific regulatory networks
  180. Abstract 2919: XBP1 and the unfolded protein response in antiestrogen resistance in breast cancer
  181. Abstract 4601: XBP1 regulated function of c-MYC and BCL2 in antiestrogen resistance in breast cancer
  182. Knowledge-guided gene ranking by coordinative component analysis
  183. DBC-1 mediates endocrine resistant breast cancer cell survival
  184. BCL2 and CASP8 regulation by NF‐κB differentially affect mitochondrial function and cell fate in antiestrogen‐sensitive and ‐resistant breast cancer cells
  185. Co-Inhibition of BCL-W and BCL2 Restores Antiestrogen Sensitivity through BECN1 and Promotes an Autophagy-Associated Necrosis
  186. Signaling Pathways in the Normal and Neoplastic Breast
  187. Cross phenotype normalization of microarray data
  188. The role of preclinical animal models in breast cancer drug development
  189. Learning a highly resolved tree of phenotypes using genomic data clustering
  190. Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer
  191. Reverse engineering module networks by PSO-RNN hybrid modeling
  192. Molecular mechanisms of resistance to HER2-targeted therapy
  193. XBP1, Unfolded Protein Response, and Endocrine Responsiveness
  194. Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells
  195. A Systems Biology Approach to Identify Affected Regulatory and Signaling Circuits in Protein Interaction Networks
  196. Biomarker identification by knowledge-driven multilevel ICA and motif analysis
  197. Identification of condition-specific regulatory modules through multi-level motif and mRNA expression analysis
  198. The role of X-box binding protein-1 in tumorigenicity
  199. Differential dependency network analysis to identify condition-specific topological changes in biological networks
  200. Gene Signaling Pathways Mediating the Opposite Effects of Prepubertal Low-Fat and High-Fat n-3 Polyunsaturated Fatty Acid Diets on Mammary Cancer Risk
  201. ERRγ Mediates Tamoxifen Resistance in Novel Models of Invasive Lobular Breast Cancer
  202. Knowledge-guided multi-scale independent component analysis for biomarker identification
  203. caBIG™ VISDA: Modeling, visualization, and discovery for cluster analysis of genomic data
  204. Network motif-based identification of breast cancer susceptibility genes
  205. Network motif-based identification of transcription factor-target gene relationships by integrating multi-source biological data
  206. The Importance of Estrogen Receptors in Breast Cancer
  207. Approaches to working in high-dimensional data spaces: gene expression microarrays
  208. Motif-directed network component analysis for regulatory network inference
  209. The properties of high-dimensional data spaces: implications for exploring gene and protein expression data
  210. A ground truth based comparative study on clustering of gene expression data
  211. Classification algorithms for phenotype prediction in genomics and proteomics
  212. Network-Constrained Support Vector Machine for Classification
  213. An Iterative Nonlinear Regression Method for Microarray Data Normalization
  214. Web-based parallel corpora for statistical machine translation
  215. Biomarker identification by knowledge-driven multi-scale independent component analysis
  216. Integrating multi-source biological data for transcriptional regulatory module discovery
  217. Progressive Loss of Estrogen Receptor α Cofactor Recruitment in Endocrine Resistance
  218. Human Tumours in Animal Hosts
  219. Human X‐Box binding protein‐1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines
  220. VISDA: an open-source caBIG™ analytical tool for data clustering and beyond
  221. The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines
  222. Caveolin-1 Tyrosine Phosphorylation Enhances Paclitaxel-mediated Cytotoxicity
  223. Gene Selection for Multiclass Prediction by Weighted Fisher Criterion
  224. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer
  225. Estrogen receptor alpha positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures
  226. Robert B. Dickson: In Memoriam (1952–2006)
  227. Endocrine therapy resistance can be associated with high estrogen receptor α (ERα) expression and reduced ERα phosphorylation in breast cancer models
  228. Robert B. Dickson
  229. 128 POSTER Vitamin E succinate inhibits the in vitro growth of pancreatic cancer cells
  230. Learning the Tree of Phenotypes Using Genomic Data and VISDA
  231. Inference of Gene Regulatory Networks from Time Course Gene Expression Data Using Neural Networks and Swarm Intelligence
  232. Inferring Network Interactions Using Recurrent Neural Networks and Swarm Intelligence
  233. Latent Variable and nICA Modeling of Pathway Gene Module Composite
  234. Physical and Functional Interactions between Cas and c-Src Induce Tamoxifen Resistance of Breast Cancer Cells through Pathways Involving Epidermal Growth Factor Receptor and Signal Transducer and Activator of Transcription 5b
  235. Composite Gene Module Discovery using Non-negative Independent Component Analysis
  236. AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines
  237. Meta-Analysis of Soy Intake and Breast Cancer Risk
  238. Optimized multilayer perceptrons for molecular classification and diagnosis using genomic data
  239. Expression patterns among interferon regulatory factor-1, human X-box binding protein-1, nuclear factor kappa B, nucleophosmin, estrogen receptor-alpha and progesterone receptor proteins in breast cancer tissue microarrays
  240. The Disposition of Reduced Haloperidol and HPP,+ Metabolites of Haloperidol, is Not Influenced by P-Glycoprotein
  241. Multidrug Resistance/P-Glycoprotein and Breast Cancer: Review and Meta-Analysis
  242. Mechanisms Mediating the Effects of Prepubertal (n-3) Polyunsaturated Fatty Acid Diet on Breast Cancer Risk in Rats
  243. The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1α/CXCL12
  244. Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis
  245. Adjuvant and neoadjuvant therapy in non-small cell lung cancer
  246. Human Tumours in Animal Hosts
  247. Antiestrogens, Aromatase Inhibitors, and Apoptosis in Breast Cancer
  248. Nutritional modulation of the cell cycle and breast cancer
  249. Common origins of MDA-MB-435 cells from various sources with those shown to have melonoma properties
  250. LCC15-MB Cells are MDA-MB-435: A Review of Misidentified Breast and prostate cell lines
  251. Evaluation of gene expression profile of keratinocytes in response to JP-8 jet fuel
  252. Expression of an estrogen receptor variant lacking exon 3 in derivatives of MCF-7 cells with acquired estrogen independence or tamoxifen resistance
  253. Interferon Regulatory Factor-1 Mediates the Proapoptotic but Not Cell Cycle Arrest Effects of the Steroidal Antiestrogen ICI 182,780 (Faslodex, Fulvestrant)
  254. Gene selection in class space for molecular classification of cancer
  255. Robust feature selection by weighted Fisher criterion for multiclass prediction in gene expression profiling
  256. Discriminatory Mining of Gene Expression Microarray Data
  257. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
  258. Estrogen Withdrawal-Induced NF-κB Activity and Bcl-3 Expression in Breast Cancer Cells: Roles in Growth and Hormone Independence
  259. Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland
  260. ATP binding cassette transporters and drug resistance in breast cancer.
  261. Animal models of endocrine-responsive and -unresponsive breast cancers
  262. Iterative normalization of cDNA microarray data
  263. Do estrogens always increase breast cancer risk?
  264. Functionally active estrogen receptor isoform profiles in the breast tumors of African American women are different from the profiles in breast tumors of Caucasian women
  265. Block principal component analysis with application to gene microarray data classification
  266. C-7 Analogues of Progesterone as Potent Inhibitors of the P-Glycoprotein Efflux Pump
  267. Constitutive Expression of the Steroid Sulfatase Gene Supports the Growth of MCF-7 Human Breast Cancer Cellsin Vitroandin Vivo1
  268. Molecular and pharmacological aspects of antiestrogen resistance
  269. Competitive and Allosteric Interactions in Ligand Binding to P-glycoprotein as Observed on an Immobilized P-glycoprotein Liquid Chromatographic Stationary Phase
  270. Maternal and Prepubertal Diet, Mammary Development and Breast Cancer Risk
  271. Genistein: Does it Prevent or Promote Breast Cancer?
  272. Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using splice targeted primer approach
  273. Development of an immobilized P-glycoprotein stationary phase for on-line liquid chromatographic determination of drug-binding affinities
  274. ER in normal and pre-cancerous breast
  275. Stromelysin-1 promotes mammary carcinogenesis
  276. Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract
  277. Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring.
  278. Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis
  279. Inhibition of estrogen receptor function promotes porcine coronary artery smooth muscle cell proliferation
  280. The influence of maternal diet on breast cancer risk among female offspring
  281. Differential distribution of protein phosphatase 2A in human breast carcinoma cell lines and its relation to estrogen receptor status
  282. Growth and phenotypic characterization of porcine coronary artery smooth muscle cells
  283. Organochlorine pesticides: an effect on estrogen activity?
  284. Progesterone in mouse mammary gland carcinogenesis
  285. Reversal of Tamoxifen Resistance of Human Breast Carcinomas In Vivo by Neutralizing Antibodies to Transforming Growth Factor- 
  286. The Estrogenicity of Selected Nutrients, Phytochemicals, Pesticides, and Pollutants
  287. Use of ERE and Reporter Gene Constructs to Assess Putative Estrogenic Activity
  288. Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells
  289. The LCC15-MB Human Breast Cancer Cell Line Expresses Osteopontin and Exhibits an Invasive and Metastatic Phenotype
  290. Maternal genistein exposure mimics the effects of estrogen on mammary gland development in female mouse offspring.
  291. Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models
  292. Animal models of breast cancer: experimental design and their use in nutrition and psychosocial research
  293. Mechanisms by which high maternal fat intake during pregnancy increases breast cancer risk in female rodent offspring
  294. Estrogen-regulated non-reproductive behaviors and breast cancer risk: Animal models and human studies
  295. Steroid metabolism in the hormone dependent MCF-7 human breast carcinoma cell line and its two hormone resistant subpopulations and
  296. A maternal diet high in n − 6 polyunsaturated fats alters mammary gland development, puberty onset, and breast cancer risk among female rat offspring
  297. Multidrug Resistance in Breast Cancer: a Meta-analysis of MDR1/gp170 Expression and Its Possible Functional Significance
  298. Breast Cancer Risk in Rats Fed a Diet High in n-6 Polyunsaturated Fatty Acids During Pregnancy
  299. Acquired estrogen independence and antiestrogen resistance in breast cancer
  300. Specific binding of estradiol to rat coronary artery smooth muscle cells
  301. Animal models of breast cancer: Their diversity and role in biomedical research
  302. Human breast cancer cell line xenografts as models of breast cancer — The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines
  303. Estrogens, Phytoestrogens, and Breast Cancer
  304. Acquisition of an Antiestrogen-Resistant Phenotype in Breast Cancer: Role of Cellular and Molecular Mechanisms
  305. Mechanisms of Resistance to Antiestrogens and Their Implications for Crossresistance
  306. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer
  307. Early Life Affects the Risk of Developing Breast Cancer
  308. Hormone dependence of breast cancer cells and the effects of tamoxifen and estrogen:31P NMR studies
  309. Acquisition of estrogen independence and antiestrogen resistance in breast cancer: association with the invasive and metastatic phenotype
  310. Cross-resistance and molecular mechanisms in antiestrogen resistance
  311. Anti‐proliferative and anti‐estrogenic effects of ICI 164,384 and ICI 182,780 in 4‐OH‐tamoxifen‐resistant human breast‐cancer cells
  312. Perinatal factors increase breast cancer risk
  313. Psychosocial factors in the development and progression of breast cancer
  314. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression
  315. Hormone resistance, invasiveness, and metastatic potential in breast cancer
  316. Opposing behavioural alterations in male and female transgenic TGFα mice: association with tumour susceptibility
  317. The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells
  318. Effect of P-glycoprotein Expression on Sensitivity to Hormones in MCF-7 Human Breast Cancer Cells
  319. Alterations in behavior, steroid hormones and natural killer cell activity in male transgenic TGFα mice
  320. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines
  321. Analysis of tyrosine kinase mRNAs including four FGF receptor mRNAs expressed in MCF‐7 breast‐cancer cells
  322. IGF-I and IGF-II expression in human breast cancer xenografts: Relationship to hormone independence
  323. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH
  324. In vitro antineoplastic activity of C7-substituted mitomycin C analogues MC-77 and MC-62 against human breast-cancer cell lines
  325. Hormonal aspects of breast cancer
  326. The Biology of Breast Tumor Progression: Acquisition of hormone independence and resistance to cytotoxic drugs
  327. Vascular Non-genomic Effects of Estrogen
  328. Reduction of the Membrane Fluidity of Human Breast Cancer Cells by Tamoxifen and 17beta-Estradiol
  329. The process of malignant progression in human breast cancer
  330. Adverse interactions between cytotoxic drugs and hormonal agents in human breast cancer cells.
  331. The inter-relationships between ovarian-independent growth, tumorigenicity, invasiveness and antioestrogen resistance in the malignant progression of human breast cancer
  332. Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo.
  333. Steroid receptors and disease: cancer, autoimmune, bone and circulatory disorders
  334. The Effects of a Constitutive Expression of Transforming Growth Factor-α on the Growth of MCF-7 Human Breast Cancer Cellsin Vitroandin Vivo
  335. Regulation of Breast Cancer Cells by Hormones and Growth Factors: Effects on Proliferation and Basement Membrane Invasiveness
  336. Regulation of Human Breast Cancer by Secreted Growth Factors
  337. Conformational and receptor binding properties of human EGF and TGF-α second loop fragments
  338. Morpho-functional effects of Phenol Red on oestrogen-sensitive breast cancer cells
  339. The ability of oestrogen to modulate the effects of cytotoxic drugs in human breast cancer cells: influence of oestrogen receptor status and choice of drug
  340. Pharmacological and suprapharmacological concentrations of both 17β-oestradiol and tamoxifen reduce the membrane fluidity of MCF-7 and MDA-MB-436 human breast cancer cells
  341. Human recombinant interferon α increases oestrogen receptor expression in ZR-75-1 human breast cancer cells and sensitizes them to the anti-proliferative effects of tamoxifen
  342. The response of human breast cancer cells to glucagon
  343. Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitises them to the anti-proliferative effects of tamoxifen
  344. The effects of Mg2+ ions or EDTA on nuclear integrity and apparent subcellular distribution of unoccupied oestrogen receptors in breast cancer cells
  345. Enhancement of methotrexate cytotoxicity towards the MDA.MB.436 human breast cancer cell line by dipyridamole
  346. The unoccupied estrogen receptor: Some comments on localization
  347. The influence of vincristine on the oestrogen-binding capacity of two human breast cancer cell lines in vitro
  348. The effects of Mg2+ or EDTA on the subcellular distribution of unoccupied oestrogen receptor in ZR-75-1 and MCF-7 cells
  349. The effect of the rate of cell proliferation on the synthesis of methotrexate poly-γ-glutamates in two human breast cancer cell lines
  350. The effect of leucovorin on the synthesis of methotrexate poly-γ-glutamates in the MCF-7 human breast cancer cell line
  351. Oestrogen receptor status and the response of human breast cancer cell lines to a combination of methotrexate and 17-beta oestradiol
  352. Reduction of the anti-metabolic and anti-proliferative effects of methotrexate by 17β-oestradiol in a human breast carcinoma cell line, MDA-MB-436
  353. The kinetics of methotrexate polyglutamate formation and efflux in a human breast cancer cell line (MDA.MB.436): The effect of insulin
  354. Failure of 5-fluorouracil and methotrexate to destroy the reproductive integrity of a human breast cancer cell line (MCF-7) growingin vitro
  355. The Estrogenicity of Selected Nutrients, Phytochemicals, Pesticides, and Pollutants: Their Potential Roles in Breast Cancer
  356. Human Breast-Cancer Xenografts as Models of the Human Disease
  357. Integrative Network Component Analysis for Regulatory Network Reconstruction
  358. Sparse Decomposition of Gene Expression Data to Infer Transcriptional Modules Guided by Motif Information
  359. Normalization of Microarray Data by Iterative Nonlinear Regression
  360. Optimizing multilayer perceptrons by discriminatory component analysis
  361. Partially-independent component analysis for tissue heterogeneity correction in microarray gene expression analysis